Repositioning Candidate Details
| Candidate ID: | R1200 |
| Source ID: | DB09043 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Albiglutide |
| Synonyms: | Albiglutide |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. |
| CAS Number: | 782500-75-8 |
| Molecular Weight: | |
| DrugBank Indication: | Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying. |
| Targets: | Glucagon-like peptide 1 receptor agonist |
| Inclusion Criteria: | Target associated |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |